<DOC>
	<DOCNO>NCT02972840</DOCNO>
	<brief_summary>This study evaluate efficacy acalabrutinib combination bendamustine rituximab ( BR ) compare placebo plus BR subject previously untreated mantle cell lymphoma .</brief_summary>
	<brief_title>A Study Bendamustine Rituximab Alone Versus Combination With Acalabrutinib Subjects With Previously Untreated Mantle Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Men woman , ≥ 65 year age . Pathologically confirm MCL . MCL require treatment prior systemic anticancer therapy receive . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 . Agreement use highly effective form contraception study 90 day last dose acalabrutinib , 6 month last dose bendamustine , 12 month last dose rituximab , whichever long . Significant cardiovascular disease uncontrolled symptomatic arrhythmia , congestive heart failure , myocardial infarction within 6 month first dose study drug , Class 3 4 cardiac disease define New York Heart Association Functional Classification , correct QT interval ( QTc ) &gt; 480 msec ( calculate use Friderica 's formula : QT/RR0.33 ) screening . Exception : Subjects control , asymptomatic atrial fibrillation screening allow enroll study . Malabsorption syndrome , disease significantly affect gastrointestinal function , resection stomach , extensive small bowel resection likely affect absorption , symptomatic inflammatory bowel disease , partial complete bowel obstruction , gastric restriction bariatric surgery , gastric bypass . Uncontrolled active systemic fungal , bacterial , viral , infection ( define exhibit ongoing signs/symptoms related infection without improvement , despite appropriate antibiotic treatment ) , intravenous anti infective treatment within 2 week first dose study drug . Concurrent participation another therapeutic clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Bruton tyrosine kinase inhibitor</keyword>
	<keyword>Btk</keyword>
	<keyword>ACP-196</keyword>
	<keyword>Mantle Cell Lymphoma</keyword>
	<keyword>acalabrutinib</keyword>
	<keyword>ACE-LY-308</keyword>
	<keyword>Treatment naive</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>non-Hodgkins</keyword>
</DOC>